Which would you rather own, VTAE with one psoriasi

Which would you rather own, VTAE with one psoriasis drug that seems to help, but has safety concerns; or CTIX, which has 4 clinical trials going for 4 different applications, including psoriasis, cancer, a new class of antibiotics, and a treatment for oral mucositis?

VTAE market cap: 148.50 million
CTIX market cap: 145.12 million.

Which one has more chance of hitting it big with at least one drug?

Quote:

---

In a four-week proof-of-concept trial, the tablet provided what Vitae said was a "clear signal of efficacy" by reducing psoriasis severity compared with placebo, though the difference fell short of statistical significance .....
Vitae said its oral treatment led to no serious side effects and was well tolerated at both 350 mg and 700 mg per day. Four patients in the high-dose group saw enzyme elevations that often point to liver damage, but each case was reversible, according to the company. No drug-related cardiac abnormalities were observed in the trial, Vitae said.

The concern over VTP-43742's safety stems from Vitae's surprise announcement earlier this month that it enrolled just 34 psoriatic patients in the trial instead of a previously planned 60. The move led many, including Stifel analyst Thomas Shrader, to conclude that Vitae had run into a toxicity issue, sending the biotech's shares down more than 40%.

And that proved to be true. Vitae told analysts on a conference call Wednesday that it had initially planned to test a third, larger dose of VTP-43742 but decided against it in light of the enzyme elevations it saw in the 700-mg group.

---

http://www.fiercebiotech.com/story/vitae-hera...2016-03-16